Epstein-Barr virus (EBV), an oncogenic herpesvirus of humans, displays selective tropism for B lymphocytes and epithelial cells. EBV tropism is thought to be determined in part by a unique host cell receptor termed CR2 (CD21). Although previous studies have demonstrated that CR2 mediates EBV binding to B cells, its role in initiating EBV infection and B-cell transformation is less certain. In the studies reported here, soluble recombinant CR2 was shown to cause substantial inhibition of EBV infection of B cells in vitro, indicating that CR2 binding initiates EBV infection. Soluble CR2 may represent a therapeutic agent for acute and chronic EBV infections in humans.
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Epstein-Barr virus (EBV), a human herpesvirus, causes infectious mononucleosis (9) , a benign lymphoproliferative syndrome, and is an important cofactor in several human malignancies (5, 10) . EBV-induced B-cell lymphomas also arise in immunocompromised patients receiving allografts and in patients infected with the human immunodeficiency virus (27) .
A 145-kilodalton (kDa) B-lymphocyte membrane glycoprotein, CR2 (CD21), serves as a receptor for EBV and the C3dg complement fragment (6, 8, 19) . EBV attachment to CR2 is mediated by a viral envelope glycoprotein (gp350/220) (17, 22, 23) , specifically by a 9-amino-acid sequence epitope located near the N-terminus of the molecule (16) . Purified CR2 (17, 18) and cells transfected with CR2 cDNA (1) bind EBV, and gp350/220 selectively absorbs CR2 from B-lymphocyte membrane extracts (6, 22) . However, EBV infection of CR2-transfected cells is inefficient (1 of 200) (1), and CR2 expression does not always correlate with EBV infection (3) .
In order to examine the role of CR2 in initiating EBV infection of B cells, a baculovirus expression system (21) was used to generate milligram amounts of the complete extracellular domain of CR2 (CD21). To produce a soluble receptor, plasmid Bluescript containing the 16-repeat form of the receptor (13) (pBS/CR2) was truncated proximal to the predicted membrane-spanning region ( Fig. 1) and was ligated to a BamHI linker immediately 5' to the transcription initiation codon. The internal BamHI site present in repeat element 10 of CR2 was also deleted by changing a single nucleotide at position 2014 in CR2 cDNA by site-directed mutagenesis (12) without changing the original amino acid sequence. Next, a transcription termination codon and BamHI site were inserted immediately following the last repeat (repeat 16) of the CR2 extracellular domain. The altered CR2 construct was then inserted downstream of the polyhedrin promoter in the pAc373 transfer vector and integrated into the Autographa californica nuclear polyhedrosis virus genome by homologous recombination (21) . Pure recombinant viruses were identified by microscopic examination and used to infect Spodoptera frugiperda clone 9 cells (Sf9). For large-scale production of CR2, 1-liter Spinner cultures of SF9 were infected. Cells were infected with recombinant virus, and soluble CR2 was isolated on day 3 from culture supernatant by immunoaffinity chromatography (20) .
Characterization of secreted recombinant CR2 protein was carried out by metabolic labeling of cells infected with recombinant baculovirus with [35S]methionine followed by immunoprecipitation and sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis. A 125-kDa protein was immunoprecipitated from the supernatants of cells infected with recombinant virus with two CR2-specific monoclonal antibodies, HB5 and OKB7, but not with an irrelevant control antibody ( Fig. 2A) . The size of the truncated recombinant molecule is smaller than that of the nontruncated 145-kDa, fully glycosylated, cell-associated CR2 but is larger than the predicted size of the 110-kDa, nonglycosylated, truncated recombinant receptor. Cells infected with the wild-type baculovirus did not produce the 125-kDa protein ( Fig. 2A , lanes 4 to 6). The HB5 monoclonal antibody was subsequently used to isolate large amounts of recombinant CR2 for functional analysis. Supernatants derived from cells infected with recombinant virus were reacted with an HB5 monoclonal antibody immunoabsorbent and after the resin was washed, the receptor was eluted with 3 M MgCI2. A highly purified receptor (>90% homogeneous) was obtained by this method (Fig. 2B) .
A CR2-specific enzyme-linked immunosorbent assay was used to determine whether the purified receptor retained ligand-binding activity. Samples of purified gp350/220 (100 ng per well) or C3dg or ovalbumin (300 ng per well) were dried on 96-well plates (Immulon II, Dynatech Industries, Inc., McLean, Va.) at 37°C for 18 h. Nonspecific binding sites were blocked by the addition of 100 ,ul of 5% bovine serum albumin in phosphate-buffered saline for 1 h at 4°C. After the blocking reagent was removed, purified CR2 diluted in 100 pl of 0.5% bovine serum albumin in phosphatebuffered saline was added with further incubation for 2 h at 22°C. CR2 binding was then detected by sequential incubations with biotinylated HB5 monoclonal antibody, streptavidin-horseradish peroxidase (Amersham Corp.), and substrate as previously described (16 CR2 bound to both immobilized recombinant gp350/220 (26) and C3dg in a dose-dependent manner, while only background binding was observed with an irrelevant protein (Fig.  3a) . In parallel studies, recombinant CR2 was assessed for its ability to compete with gp350/220 for binding to B cells. Approximately 20 to 40 ng of purified gp350/220 was coated onto fluorescent microspheres (Baxter, Chicago, Ill.) as previously described. Nonspecific binding sites were blocked by the addition of 5% bovine serum albumin for 1 h at 4°C. The microspheres were then pelleted, suspended in phosphate-buffered saline, and incubated with buffer alone or with various amounts of CR2 for 18 h at 4°C. These samples were then directly reacted with 5 x 105 cells for 1 h at 4°C and then prepared for fluorescence-activated cell sorter analysis as previously described (16) . CR2 caused dose-dependent inhibition of gp350/220 fluorescent-microsphere binding to Raji B cells (Fig. 3b) addition of unseparated peripheral blood mononuclear cells. After further incubation with EBV and CR2, the cells were washed, cultured for 14 to 21 days, and assessed for transformation as previously described (15) . Preincubation of EBV with CR2 resulted in substantial inhibition (65 to 70%) of EBV infection, as measured by the outgrowth of trans- formed colonies and by [3H]thymidine incorporation (Fig.   4A ). The ability of CR2 to inhibit EBV infection was not due to toxic effects of the receptor on the B cells, since the highest dose of CR2 used in this experiment (7.5 pg) did not abolish infection of B cells if EBV was allowed to bind to B cells prior to being exposed to the receptor (Fig. 4A) . In (Fig. 4B) , various amounts of EBV were preincubated with a constant amount of CR2 (10 ,ug) prior to the addition of B cells. EBV-induced B-cell transformation was reduced by 70 to 90% by preincubation with CR2 (Fig. 4B) 
